Changes in the Cannabinoid Receptor Binding, G Protein Coupling, and Cyclic AMP Cascade in the CNS of Rats Tolerant to and Dependent on the Synthetic Cannabinoid Compound CP55,940
- 1 November 2000
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 75  (5) , 2080-2086
- https://doi.org/10.1046/j.1471-4159.2000.0752080.x
Abstract
Chronic exposure to CP55,940 produced a significant downâregulation of cannabinoid receptors in the striatum, cortex, hippocampus, and cerebellum of rat brain. At 24 h after SR141716âprecipitated withdrawal, we observed a tendency to return to basal levels in the striatum and cortex, whereas the specific binding remained lower in the hippocampus and cerebellum. When we surveyed cannabinoid receptorâactivated G proteins, in chronic CP55,940âtreated rats the guanosine 5âČâOâ(3â[35S]thiotriphosphate) ([35S]GTPÎłS) binding assay revealed a decrease of activated G proteins in the striatum, cortex, and hippocampus, whereas no significant changes were seen in the cerebellum. At 24 h after the SR141716âprecipitated withdrawal, [35S]GTPÎłS binding increased compared with that of rats chronically exposed to CP55,940, attaining the control level except for cerebellum, where we observed a trend to overcome the control amounts. Concerning the cyclic AMP (cAMP) cascade, which represents the major intracellular signaling pathway activated by cannabinoid receptors, in the cerebral areas from rats chronically exposed to CP55,940 we found alteration in neither cAMP levels nor protein kinase A activity. In the brain regions taken from CP55,940âwithdrawn rats, we only observed a significant upâregulation in the cerebellum. Our findings suggest that receptor desensitization and downâregulation are strictly involved in the development of cannabinoid tolerance, whereas alterations in the cAMP cascade in the cerebellum could be relevant in the mediation of the motor component of cannabinoid abstinence.Keywords
This publication has 24 references indexed in Scilit:
- Chronic Î-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regionsNeuropharmacology, 2000
- Comparison of novel cannabinoid partial agonists and SR141716A in the guineaâpig small intestineBritish Journal of Pharmacology, 2000
- Chronic â”9âTetrahydrocannabinol Treatment Produces a TimeâDependent Loss of Cannabinoid Receptors and Cannabinoid ReceptorâActivated G Proteins in Rat BrainJournal of Neurochemistry, 1999
- Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant micePublished by Elsevier ,1999
- Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with Îâ9âtetrahydrocannabinolBritish Journal of Pharmacology, 1998
- Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptorsBritish Journal of Pharmacology, 1998
- Activation of Corticotropin-Releasing Factor in the Limbic System During Cannabinoid WithdrawalScience, 1997
- Physical withdrawal in rats tolerant to Î9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonistEuropean Journal of Pharmacology, 1995
- Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic studyBrain Research, 1993
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976